In the latest market close, Organon (OGN) reached $20.63, with a -0.77% movement compared to the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.16%. On the other hand, the Dow registered a gain of 0.04%, and the technology-centric Nasdaq increased by 0.49%. Prior to today's trading, shares of the pharmaceutical company had lost 0.91% over the past month. This has lagged the Medical sector's gain of 2.32% and the S&P 500's gain of 3.22% in that time. The upcoming earnings rel ...

Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision. Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as w ...

Furthermore, it would be beneficial for investors to monitor any recent shifts in analyst projections for Organon. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability. The pharmaceutical company's shares have seen a decrease of 7.33% over the last month, not keeping up with the Medical sector's gain of 0.03% and the S&P 500's gain of 3.59%. OGN's full-year Z ...

Last Reported Results and Surprise History Over the past month, shares of this pharmaceutical company have returned -5.1%, compared to the Zacks S&P 500 composite's +3.1% change. During this period, the Zacks Medical Services industry, which Organon falls in, has gained 0.9%. The key question now is: What could be the stock's future direction? Revisions to Earnings Estimates We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the la ...

OGN has rallied 8.8% over the past four weeks, and the company is a Zacks Rank #1 (Strong Buy) at the moment. This combination suggests OGN could be on the verge of another move higher. The bullish case solidifies once investors consider OGN's positive earnings estimate revisions. No estimate has gone lower in the past two months for the current fiscal year, compared to 3 higher, while the consensus estimate has increased too. With a winning combination of earnings estimate revisions and hitting a key techn ...

Organon (OGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares of this pharmaceutical company have returned +9.2% over the past month versus the Zacks S&P 500 composite's +3.2% change. The Zacks Medical Services industry, to which Organon belongs, has lost 2.8% over this period. Now the key question is: Where could the stock be headed in the near term? Although media repo ...

Organon (OGN) could be a solid choice for investors given the company's remarkably improving earnings outlook. While the stock has been a strong performer lately, this trend might continue since analysts are still raising their earnings estimates for the company. The upward trend in estimate revisions for this pharmaceutical company reflects growing optimism of analysts on its earnings prospects, which should get reflected in its stock price. After all, empirical research shows a strong correlation between ...

Which Healthcare Company Is Best? Joe Raedle/Getty Images News Organon (NYSE:OGN) and Pfizer (PFE) both yield over 5% and are the two highest yielding pharmaceuticals. Bristol-Myers (BMY) is the only other pharmaceutical company that offers a yield above 5% that like Organon and Pfizer, can compete with similarly yielding Treasuries (i.e., those with maturities 12 months or less). Three troubling years of declining double-digit annualized returns have resulted in these well-above average yields. Pfizer ha ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ Form 10-Q ________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File No. 001-40235 Organon & Co. (Exact name of registrant as specified i ...

Organon (OGN) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.The power of a ch ...